PPARs: molecular targets in the pharmacogenomics era.
The recent global increase in prevalence of diseases like obesity, type 2 diabetes and hypertension in westernized societies is unfortunately not paralleled by our full understanding of the causative mechanisms. It is now firmly established that the interacting genetic and environmental (diet, smoking) components together determine the development and severity of the particular condition, which makes detailed dissection of such complex traits even more complicated. In effect, there is an unmet urgent need for molecular targets so we can directly modulate the causative factors and devise effective preventive and therapeutic algorithms. Among the most promising molecular targets for treatment of metabolic syndrome-related conditions identified so far, the group of three lipid-sensors, the peroxisome proliferator-activated receptors (PPARs) clearly stands out. The review focuses on pharmacogenetic aspects of recent developments in PPAR biology.
Seda
O
O
Institute of Biology and Medical Genetics of the First Faculty of Medicine, Charles University in Prague, Czech Republic. oseda@lf1.cuni.cz
Sedová
L
L
D000818:Animals; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000503:physiopathology*; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D045162:Thiazolidinediones / Q000627:therapeutic use
D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones